Sökning: "Gustav Ullenhag"

Hittade 5 avhandlingar innehållade orden Gustav Ullenhag.

  1. 1. Vaccine Therapy of Colorectal Cancer Patients with Tumor Associated Antigens

    Författare :Gustav Ullenhag; Håkan Mellstedt; Carl Magnusson; Bengt Glimelius; Torgny Stigbrand; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Oncology; Oncology; Colorectal cancer; GM-CSF; vaccination; CEA; ALVAC-KSA; IgG subclass; epitopes; Onkologi; Oncology; Onkologi; Oncology; onkologi;

    Sammanfattning : In this thesis, two different vaccines were evaluated as adjuvant therapy for patients with colorectal cancer. The ability of the two candidate vaccines to generate antigen-specific cellular and humoral responses, respectively, was studied. LÄS MER

  2. 2. Antibody-based Cancer Immunotherapy : Personalization, response prediction and safety considerations

    Författare :Mohamed Eltahir; Sara Mangsbo; Patrick Micke; Gustav Ullenhag; Marit Inderberg; Uppsala universitet; []
    Nyckelord :;

    Sammanfattning : Antibody-based therapeutics have remarkably improved the field of immuno-oncology. Multiple monoclonal antibodies (mAbs) are approved for clinical use, and numerous antibodies are under clinical development. The scope of this thesis is to study the personalization of antibody-based immunotherapeutics and tools to predict their efficacy and safety. LÄS MER

  3. 3. Intratumoral CD40 stimulating therapy in patients with advanced cancer

    Författare :Sandra Irenaeus; Gustav Ullenhag; Angelica S. Loskog; Poulam Patel; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; CD40; CD40L; immunotherapy; early clinical studies; advanced cancer; intratumoral administration; Medicinsk vetenskap; Medical Science; Oncology; Onkologi;

    Sammanfattning : CD40-CD40L interaction activates DCs to become highly efficient APCs and skews the adaptive immune response towards a Th I phenotype driving cytotoxic T cells, M1 macrophages and natural killer cells. Furthermore, engagement of CD40L to CD40 positive cancer cells can have direct anti-proliferative effects, induce apoptosis and increase expression of MHC and other co-stimulatory molecules, thereby enhancing cancer cell recognition. LÄS MER

  4. 4. Intratumoral Predictive Markers in Metastatic Renal Cancer Patients

    Författare :Marjut Niinivirta; Gustav Ullenhag; Gunilla Enblad; Sten Nilsson; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Renal cell cancer; predictive marker; tyrosine kinase inhibitor; tissue microarray; cubilin; annexin A1; PKLR; ELTD1; Oncology; Onkologi;

    Sammanfattning : There is no established predictive marker for the treatment of metastatic renal cell cancer (mRCC) patients. With a predictive marker, patients unlikely to respond could be selected upfront and offered other therapy options. Thereby, unnecessary toxicity could be avoided and costs would be reduced. LÄS MER

  5. 5. Experimental treatment of patients with disseminated malignant melanoma

    Författare :Aglaia Schiza; Gustav Ullenhag; Angelica Loskog; Sara Mangsbo; Thomas Tötterman; Ola Winqvist; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Malignant melanoma; AdCD40L; immunotherapy; proteomics; DW-MRI; FDG-PET CT; prediction; early response; BRAF-inhibitor; vemurafenib; Oncology; Onkologi;

    Sammanfattning : Malignant melanoma (MM) is the deadliest skin cancer with an ever-increasing incidence. New treatments have improved the prognosis for patients with advanced MM. Still, most patients do not respond, and the side effects can be severe, underlining the need for better therapies. LÄS MER